BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 3012818)

  • 1. Modification of platelet functions by monobromobimane, a fluorescent thiol group label.
    Zucker MB; Mauss EA
    Thromb Haemost; 1986 Apr; 55(2):228-34. PubMed ID: 3012818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the thiol group inhibitor monobromobimane and other inhibitors on the composition of the platelet cytoskeletal core and its association with glycoprotein IIIa.
    Puszkin EG; Mauss EA; Milot DC; Zucker MB
    J Cell Biochem; 1989 Apr; 39(4):339-54. PubMed ID: 2498343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathways responsible for platelet hypersensitivity in rats with diabetes. I. Streptozocin-induced diabetes.
    Winocour PD; Kinlough-Rathbone RL; Mustard JF
    J Lab Clin Med; 1986 Feb; 107(2):148-53. PubMed ID: 3080538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate.
    Cattaneo M; Lecchi A; Randi AM; McGregor JL; Mannucci PM
    Blood; 1992 Dec; 80(11):2787-96. PubMed ID: 1333302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibitory effects of exogenous arachidonic acid on rabbit platelet aggregation and the release reaction.
    Cattaneo M; Kinlough-Rathbone RL; Perry DW; Chahil A; Vickers JD; Lam SC; Packham MA; Mustard JF
    Blood; 1982 Nov; 60(5):1179-87. PubMed ID: 6289942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arachidonate metabolism, 5-hydroxytryptamine release and aggregation in human platelets activated by palmitaldehyde acetal phosphatidic acid.
    Brammer JP; Maguire MH
    Br J Pharmacol; 1984 May; 82(1):61-72. PubMed ID: 6428500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets.
    Johnson GJ; Leis LA; Francis GS
    Circulation; 1986 Apr; 73(4):847-54. PubMed ID: 3004784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
    Krishnamurthi S; Westwick J; Kakkar VV
    Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected effects of aurin tricarboxylic acid on human platelets.
    Kinlough-Rathbone RL; Packham MA
    Thromb Haemost; 1992 Aug; 68(2):189-93. PubMed ID: 1412166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzodiazepines inhibit human platelet activation: comparison of the mechanism of antiplatelet actions of flurazepam and diazepam.
    Romstedt K; Huzoor-Akbar
    Thromb Res; 1985 May; 38(4):361-74. PubMed ID: 2990062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of epinephrine on fibrinogen receptor exposure by aspirin-treated platelets and platelets from concentrates in response to ADP and thrombin.
    Peerschke EI
    Am J Hematol; 1984 May; 16(4):335-45. PubMed ID: 6326566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin-induced platelet aggregation involves an indirect proteolytic cleavage of aggregin by calpain.
    Puri RN; Zhou FX; Bradford H; Hu CJ; Colman RF; Colman RW
    Arch Biochem Biophys; 1989 Jun; 271(2):346-58. PubMed ID: 2543293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of phospholipase inhibitor mepacrine on platelet aggregation, the platelet release reaction and fibrinogen binding to the platelet surface.
    Winocour PD; Kinlough-Rathbone RL; Mustard JF
    Thromb Haemost; 1981 Jun; 45(3):257-62. PubMed ID: 7281105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the thrombin-platelet reactions by DuP 714.
    Chiu AT; Mousa SA; Pease LJ; Roscoe WA; Bozarth JM; Reilly TM; Smith RD; Timmermans PB
    Biochem Biophys Res Commun; 1991 Sep; 179(3):1500-8. PubMed ID: 1930190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo functions of thrombin-treated platelets.
    Reimers HJ; Kinlough-Rathbone RL; Cazenave JP; Senyi AF; Hirsh J; Packham MA; Mustard JF
    Thromb Haemost; 1976 Feb; 35(1):151-66. PubMed ID: 785686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation by adrenaline of agonist-induced responses in normal human platelets in vitro.
    Haaland HD; Holmsen H
    Platelets; 2011; 22(5):328-37. PubMed ID: 21388249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colloidal gold labelling of fibrinogen receptors in epinephrine- and ADP-activated platelet suspensions.
    Oliver JA; Albrecht RM
    Scanning Microsc; 1987 Jun; 1(2):745-56. PubMed ID: 3616571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A defect of platelet aggregation associated with an abnormal distribution of glycoprotein IIb-IIIa complexes within the platelet: the cause of a lifelong bleeding disorder.
    Hardisty R; Pidard D; Cox A; Nokes T; Legrand C; Bouillot C; Pannocchia A; Heilmann E; Hourdillé P; Bellucci S
    Blood; 1992 Aug; 80(3):696-708. PubMed ID: 1638023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a potent platelet aggregation inhibitor from Agkistrodon rhodostoma snake venom.
    Huang TF; Wu YJ; Ouyang C
    Biochim Biophys Acta; 1987 Sep; 925(3):248-57. PubMed ID: 3620499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of Na+/H+ exchange block stimulus-provoked arachidonic acid release in human platelets. Selective effects on platelet activation by epinephrine, ADP, and lower concentrations of thrombin.
    Sweatt JD; Johnson SL; Cragoe EJ; Limbird LE
    J Biol Chem; 1985 Oct; 260(24):12910-9. PubMed ID: 2997148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.